Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

IMC-C225 monoclonal antibody against epidermal growth factor regulatory update

February 5, 2001 8:00 AM UTC

The FDA granted fast track designation for IMC-C225 to treat refractory colorectal carcinoma. IMC-C225 is in Phase III testing in combination with radiotherapy and chemotherapy to treat advanced head ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article